WHAT DOES THIS MEAN FOR PATIENTS?We looked at the parts of the *in vitro* fertilization process that might influence whether a pregnancy after the transfer of a single embryo results in identical (monozygotic) twins. Based on our findings, we think that couples should be advised that transferring a single embryo, especially if it is at the blastocyst stage (Day 5 or 7 of embryo development), is not a guarantee for having only one baby. Furthermore, a pregnancy of identical twins after fresh embryo transfer is linked with an increased chance of premature delivery and a baby dying during late pregnancy, during childbirth or after birth.

Introduction {#sec1}
============

In humans, twins can result either from the ovulation and fertilization of two oocytes with the outcome of dizygotic twins (DZT) or from the splitting of a single embryo at some stage of its early development, resulting in monozygotic twins (MZT).

It is widely recognized that ART is associated not only with an increased incidence of DZT but also an increased risk of MZT ([@ref1]). A population study suggests that the risk of MZT is \~60% higher among offspring of ART than after spontaneous conception ([@ref25]).

Recent systematic reviews and meta-analyses, including articles from 1995 to 2018, have shown an increased incidence of MZT in women undergoing ART when compared with spontaneous conception ([@ref12]; [@ref3]). Actually, MZT accounts for 0.4% of spontaneous pregnancies ([@ref5]; [@ref4]; [@ref17]) and up to 4.9% of pregnancies after ART ([@ref12]; [@ref3]). This increased risk of MZT after ART has raised considerable clinical concern because MZT not only increases maternal and fetal complications associated with multiple gestation by itself but also increases the rates of premature delivery, fetal growth discordance and perinatal mortality when compared with DZT ([@ref6]; [@ref7]). Indeed, [@ref10] reported a perinatal mortality of 5% in DZT and 11.6% in MZT.

Although the ultimate cause of the increased risk of MZT after ART is unknown, many factors inherent to women undergoing fertility treatments and ART itself have been postulated as possible causes such as maternal age, type of insemination, embryo developmental stage at embryo transfer (ET), use of assisted hatching (AH), embryo biopsy for preimplantation genetic testing (PGT) and frozen-thawed embryo transfer (FET) ([@ref15]; [@ref13]; [@ref3]).

The objective of this study was to assess possible factors associated with MZT in a large cohort of women undergoing single embryo transfer (SET) after autologous IVF and ICSI and to evaluate the gestational and perinatal outcomes of MZT.

Materials and Methods {#sec2a}
=====================

Data was obtained from the Latin American Registry of ART (RLA), which collects data on \~80% of treatment cycles performed in the region and which are published annually by RBMO ([@ref30]). Follow-up of each case was possible since RLA has been a cycle-based multinational registry since 2012. All centers reporting to the registry have been certified by an accreditation team consisting of a biologist and clinician from a different country. There are strict regulations, including personnel, equipment and facilities, quality controls and minimum standards of success that need to be accomplished before the data from a specific center is included in the registry.

Data was obtained from 2925 clinical pregnancies taking place after autologous IVF/ICSI and fresh SET, performed between January 2012 and December 2016. Also, in order to study the effect of FET on MZT, 3085 clinical pregnancies obtained after SET/FET in the same period of time were examined. Data regarding pregnancies generated after SET of embryos resulting from vitrified/warmed oocytes was available since 2015 but, because there were only a few cases, was not included in this study (60 clinical pregnancies). Only pregnancies having an ultrasound at 6--8 weeks of amenorrhea and followed up until birth and the early neonatal period were included in this study. MZT were diagnosed when two gestational sacs and/or two embryos with fetal heartbeats were observed.

The terminology used corresponds to definitions adopted by the International Glossary of Infertility and Fertility Care ([@ref29]).

Factors possibly associated with MZT {#sec3}
------------------------------------

The following biomedical data with possible associations with MZT were studied: maternal age in completed years, type of insemination (IVF or ICSI), AH, stage of embryo development at the time of ET (cleavage stage embryo or blastocyst), elective SET (eSET), PGT and FET.

Clinical outcome {#sec4}
----------------

Pregnancies were followed until birth and the early neonatal period in order to assess the rate of miscarriage and stillbirths, gestational age at birth, neonatal weight and early neonatal mortality.

Statistical analysis {#sec5}
--------------------

Statistical analyses were completed using Stata software, version 14.0 for Mac® (Statcorp, TX, USA). Descriptive statistics were calculated as counts and percentages or mean and SD. The baseline sample characteristics were compared between the MZT and singleton groups using Fisher's exact tests. MZT rates were obtained for each factor and odds ratio (OR) with 95% CI calculated. Furthermore, multivariable logistic regression was preformed to account for the previously mentioned risk factors studied. A *P* value was considered significant if \<0.05.

Ethical approval {#sec6}
----------------

As part of the accreditation process, all participating institutions agreed to have their data shared with and published by RLA. On the other hand, as part of the institutional consent forms used by REDLARA, all patients are informed and consent obtained to have their unindividualized data used for clinical studies. Therefore, no other consent form was requested for the scientific analysis of the data collected for this study.

Results {#sec7}
=======

There were 76 MZT out of 2925 clinical pregnancies in fresh SET (2.6%) and 69 MZT out of 3085 clinical pregnancies in FET (2.2%) (OR = 0.85, 95% CI 0.61--1.19) ([Table I](#TB1){ref-type="table"}). There was one further case of MZT among 69 clinical pregnancies resulting from SET of embryos obtained from vitrified/warmed oocytes, not included in [Table I](#TB1){ref-type="table"}.

###### Comparison of monozygotic twin rates between fresh and frozen-thawed single embryo transfer.

                                  Singletons   MZT   MZT rate   OR (95% CI)         *P* value^(a)^
  ------------------------------- ------------ ----- ---------- ------------------- ----------------
  Fresh embryo transfer           2849         76    2.6        0.85 (0.61--1.19)   0.361
  Frozen-thawed embryo transfer   3016         69    2.2                            

MZT: monozygotic twins; OR: odds ratio

^(a)^Fisher's exact tests

A comparison of MZT rates by age category is shown in [Table II](#TB2){ref-type="table"}. The 76 MZT after fresh ET were distributed in all age categories from ≤34 to ≥41 years old, with a similar proportion at every age interval (*P* = 0.989).

###### Comparison of MZT rates between different age-categories with fresh single embryo transfer.

  Age (years)   Singletons (2849)   MZT (76)   MZT rate^(a)^ (%)
  ------------- ------------------- ---------- -------------------
  ≤34           1236                31         2.4
  35--36        507                 18         3.4
  37--38        510                 12         2.3
  39--40        369                 10         2.6
  ≥41           227                 5          2.2

^(a)^Fisher's exact tests. *P =* 0.989

[Table III](#TB3){ref-type="table"} shows the association between possible risk factors and the occurrence of MZT after fresh SET. A statistically significantly increase in MZT rate was observed with blastocyst compared with cleavage stage ET (3.4 versus 2.0%, respectively; OR = 1.70, 95% CI 1.05--2.76). When confounding variables were considered, performing a multivariable logistic regression of the factors included in this study, eSET was also significantly associated with an increase in the odds of MZT (OR = 1.74, 95% CI 1.04--2.92) ([Table IV](#TB4){ref-type="table"}). In cases of MZT after eSET, the proportion of blastocyst ET was 76.5% compared with 39% in MZT after the transfer of only one blastocyst because there were no more embryos available for transfer (oSET). Furthermore, all blastocysts transferred in cases of MZT after eSET were on Day 5, compared with 20% of Day 6 blastocysts in MZT after oSET. Moreover, there were 23/34 (67.6%) cases of MZT after eSET with three or more embryos cryopreserved.

###### MZT rates for each risk factor after fresh single embryo transfer and univariable logistic regression analysis.

  Risk factors                     Singletons (2849)   MZT (76)   MZT rate (%)   OR (95% CI)         *P* value
  -------------------------------- ------------------- ---------- -------------- ------------------- -----------
  ICSI                             2428                64         2.6            0.92 (0.50--1.90)   0.806
  IVF                              421                 12         2.8                                
  With assisted hatching           499                 11         2.2            0.80 (0.37--1.54)   0.490
  Without assisted hatching        2350                65         2.7                                
  Blastocyst transfer              1201                42         3.4            1.70 (1.05--2.76)   0.022
  Cleavage-stage embryo transfer   1648                34         2.0                                
  Elective embryo transfer         1008                34         3.3            1.48 (0.91--2.40)   0.092
  Non-elective embryo transfer     1841                42         2.3                                
  With PGT                         215                 6          2.7            1.05 (0.37--2.44)   0.909
  Without PGT                      2634                70         2.6                                

PGT: preimplantation genetic testing

###### Multivariable logistic regression analysis of variables likely to be associated with MZT after fresh single embryo transfer.

  ------------------------------------------------------------------
  Risk factors                      OR (95% CI)          *P* value
  --------------------------------- -------------------- -----------
  Age\                              Reference\           0.878\
  ≤34 years\                        1.05 (0.54--2.01)\   0.581\
  35--36 years\                     0.84 (0.46--1.53)\   0.404\
  37--38 years\                     0.73 (0.37--1.49)\   0.064
  39--40 years\                     0.25 (0.05--1.08)    
  ≥41 years                                              

  IVF                               1.45 (0.97--2.17)    0.067

  Without assisted hatching         1.05 (0.72--1.55)    0.767

  Blastocyst embryo transfer        2.17 (1.04--2.92)    0.002

  Elective single embryo transfer   1.74 (1.04--2.92)    0.033

  PGT                               0.97 (0.31--2.01)    0.632
  ------------------------------------------------------------------

[Table V](#TB5){ref-type="table"} shows the outcome of clinical pregnancies in singletons and MZT after fresh and FET.

###### Clinical outcome of singletons and MZT from fresh and frozen-thawed single embryo transfer.

                                                            Fresh embryo transfer   Frozen-thawed embryo transfer                                           
  --------------------------------------------------------- ----------------------- ------------------------------- ---------- ------------ --------------- ----------
  Miscarriage *N* (%)                                       347 (12.2)              16 (21.1)                       0.032      321 (10.5)   8 (11.6)        0.697
  Induced abortion *N* (%)                                  8 (0.3)                 0                               \-         16 (0.5)     0               \-
  Stillbirth *N* (‰)[^(a)^](#tblfn3){ref-type="table-fn"}   32 (13.0)               2 (16.9)^(d)^                   0.667      13 (4.9)     2 (16.7)^(d)^   0.134
  Live born deliveries *N*                                  2462                    59                              \-         2666         60              \-
  Newborns *N*                                              2462                    118                             \-         2666         120             \-
  Gestational age at birth (weeks ± SD)                     37.8 ± 1.9              35.1 ± 3.1                      \<0.0001   37.9 ± 2.0   34.9 ± 2.7      \<0.0001
  Extremely preterm birth \<28 weeks *N* (%)                17 (0.7)                4 (3.4)                         0.013      16 (0.6)     2 (1.7)         0.180
  Birth weight (grams ± SD)                                 3091 ± 518              2243 ± 580                      \<0.0001   3200 ± 538   2305 ± 471      \<0.0001
     Very low birth weight    \<1500 g N (%)                14 (0.6)                8 (6.8)                         \<0.0001   14 (0.5)     4 (3.3)         0.006
     Neonatal death *N* (‰)^(b)^                            7 (2.9)                 7 (59.3)                        \<0.0001   7 (2.6)      0               \-
     Perinatal mortality *N* (‰)^(c)^                       39 (15.8)               9 (76.3)                        0.003      20(7.5)      2(16.7)         0.244

^(a)^Expressed per 1000 newborns

^(b)^Expressed per 1000 newborns

^(c)^Expressed per 1000 newborns

^(d)^Stillbirth of both fetuses in one pregnancy

^(e)^Fisher's exact tests

Gestational age at birth and neonatal weight were significantly reduced in MZT compared with singletons in fresh and FET. Very low birth weight (\<1500 grams) was also significantly higher in MZT than singletons. There were no neonatal deaths in MZT after FET compared with seven cases after fresh transfers and perinatal mortality was significantly increased in MZT after fresh ET but not after FET.

Discussion {#sec8}
==========

The results of this study provide an overall similar proportion of MZT in 2925 clinical pregnancies after IVF/ICSI with fresh SET (2.6%) and 3085 clinical pregnancies after SET/FET (2.2%). This is much higher than the 0.4% rate observed in spontaneous pregnancies ([@ref5]; [@ref4]; [@ref17]) and confirms previous data reported in both recent systematic reviews and a meta-analysis ([@ref12]; [@ref3]), which showed an increased risk of MZT after ART from fresh ET and FET when compared with MZT rate in spontaneous pregnancies.

[@ref12]) reported a higher rate of MZT following blastocyst transfer when compared with cleavage stage ET. Furthermore, [@ref3]) not only reported an association between extended culture with blastocyst transfer and MZT but also showed an increase in MZT in women younger than 35 years old and a statistically significant association between IVF and AH with MZT, that we could not demonstrate. However, most of the studies included in these meta-analyses did not report the number of embryos transferred and MTZ was assumed to exist when the total number of embryo poles identified by ultrasound exceeded the number of embryos transferred, which is less accurate than the assessment of MZT when only one embryo is transferred. Moreover, data from both meta-analyses did not allow appropriate control by different variables influencing the splitting of a single embryo, which ends in confounding results.

On the other hand, controversial results have been reported in studies assessing the incidence of MTZ in only SET cycles. While several authors ([@ref17]; [@ref21]; [@ref22]; [@ref14]; [@ref20]; [@ref13]) concluded that blastocyst transfer is associated with an increased risk of MZT, [@ref24] not find such an association.

Our study showed a significant increase in MZT after the transfer of blastocysts compared with cleavage-stage embryos (3.4 versus 2.0%, respectively; OR = 1.70, 95% CI 1.05--2.76). Furthermore, after correcting for possible confounding variables, performing a multivariable logistic regression of the factors considered in this study for fresh ET, not only blastocyst transfer but also eSET were predictors that were statistically significantly associated with an increase in the odds of MZT. Conversely, we could not demonstrate a relation between maternal age, type of insemination (IVF/ICSI), AH and PGT with MZT when fresh ET was performed.

The ultimate cause of MZT is still unknown, but definitely, it seems to be associated with prolonged *in vitro* culture ([@ref16]). Luke *et al*. also suggested that MZT might be related to the transfer of high-quality embryos, which are more often transferred in eSET because a better selection of the best embryo from a cohort occurs and cryopreservation of surplus embryos is performed ([@ref17]). They hypothesized that these embryos could be more sensitive to changes in temperature and pH during culture, which might result in higher rates of MZT after blastocyst transfer ([@ref17]). The question arises as to which are the underlying conditions, inherent to eSET, which may increase the rate of MZT. Two factors are worth mentioning from our study: first, all blastocysts transferred in eSET were at Day 5 while 20% of transfers in oSET were at Day 6 or 7; second, in 23/34 eSET (67.6%), there were three or more blastocysts available to freeze. One may assume that women having MZT are overall more fertile or reproductively efficient, but if there are more embryos to choose from at the time of transfer, it would be interesting to elucidate if the degree of expansion or other morphologic characteristics may influence embryo splitting. Unfortunately, the RLA does not register embryo morphology at the time of transfer since this has never been standardized, but it is perhaps something worth looking at within institutions where the criteria for embryo quality assessment are standardized.

Most publications regarding MZT in ART have focused mainly on determining its incidence and etiology, but few studies have addressed clinical outcomes of MZT after ART. Cohort studies assessing clinical outcome of twin pregnancies conceived by ART have shown an increased risk of premature delivery, lower birth weight, major neonatal morbidity and neonatal death in MZT *versus* DZT ([@ref8]; [@ref26]; [@ref11]). Our study demonstrated significantly reduced gestational age at birth and neonatal weight in MZT compared with singletons, which has been also reported by other authors ([@ref28]; [@ref19]), but no differences in stillbirths between singletons and MZT. Perinatal mortality was higher in MZT compared with the birth of singletons; however, this was only significant in births generated after fresh SET, which is probably due to less extremely preterm births and very low birth weights, with no neonatal deaths in MZT after FET. Actually, the overall outcome was poorer after fresh ET than FET. Concerning this issue, although published studies have some limitations because they are observational and not randomized, available evidence suggests improved perinatal outcomes after FET ([@ref2]; [@ref18]). Perhaps, this could be interpreted as the consequence of an ET in a more physiological environment which, together with the inherent risks of MZT, could also explain the 2-fold higher miscarriage rate we observed in MZT after fresh ET than FET.

The main strengths of this study are the large number of cases of SET included in it, the thoroughness of the registry software and the rigor in follow-up by centers reporting to RLA, which allows adjustment for the most relevant confounding variables and to obtain reliable clinical outcomes. A potential limitation of the current study is that data obtained from RLA is based on early ultrasound with fetal heart beats at 6--8 weeks of amenorrhea and cannot determine either whether one embryo loss occurred before this ultrasound or MZT chorioamnionicity, which is relevant for pregnancy outcome and prognosis ([@ref6]).

Based on our findings, we believe that patients undergoing IVF/ICSI should be educated that SET, especially of blastocysts, is not a guarantee for delivering singletons and that MZT after fresh ET is associated with a significantly higher risk of miscarriage, prematurity and perinatal death.

However, patients should not be discouraged to undergo eSET at blastocyst stage because enhanced embryo selection, higher pregnancy rates, a lower number of transferred embryos and lower multiple pregnancy rates have been reported when extended culture and blastocyst instead of cleavage-stage ET is performed ([@ref9]). Moreover, good prognosis patients should be encouraged to undergo blastocyst eSET because it has been demonstrated that this practice reduces multiple pregnancies without compromising cumulative live birth rates ([@ref23]).

We believe there are three options for future development: first, as suggested by [@ref27]), include the assessment of inner cell mass (ICM) splitting prior to ET in current blastocyst embryo grading, in order to avoid transferring these embryos in favor of blastocysts with intact ICM and reduce the risk of MZT; second, identify dynamic markers capable of recognizing cleaving embryos that will reach blastocyst stage, in order to transfer them at an early stage of development and therefore reduce MZT rates; third, opt for FET as the preferred mode of treatment in SET in order to reduce perinatal mortality associated with MZT. Of course, the latter option could be undertaken after proper randomized trials with sufficient follow-up have been conducted and shown no adverse effect.

We thank Carolina Musri, administrator of the RLA, and all centers reporting to the registry for their efforts, which allow this research.

Authors' roles {#sec9}
==============

All authors were involved in the design of the study, interpretation of data and revision of the final manuscript.

Funding {#sec10}
=======

No specific funding was received to undertake this study.

Conflict of interest {#sec11}
====================

None of the authors declare a conflict of interest.
